Confronto
Bremelanotide vs. Terlipressin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
189691-06-3
14636-12-5
Peso molecolare
1025.18 g/mol
1227.37 g/mol
Emivita
2.7 h
nessun dato
Sequenza
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHnessun dato
Meccanismo d'azione
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Terlipressin
Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
1
di cui sull'uomo
5
1
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Bremelanotide and Terlipressin?
- Bremelanotide is classified as "Ricerca (altro)", while Terlipressin is classified as "Ricerca (altro)". Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Bremelanotide or Terlipressin?
- The highest available evidence level is "RCT sull'uomo" for Bremelanotide and "RCT sull'uomo" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Bremelanotide and Terlipressin in Germany and the United States?
- Germania: Bremelanotide — Non approvato, Terlipressin — Su prescrizione. Stati Uniti: Bremelanotide — Su prescrizione, Terlipressin — Su prescrizione. These are factual summaries with source and review date on the individual pages.